Research Areas - Cancer metabolism
Metabolic reprogramming is widely recognized as a hallmark of cancer, and the aberrant metabolic phenotype of cancer cells provides potential therapeutic opportunities. Although no drugs targeting specific metabolic pathways are currently approved for prostate cancer treatment, multiple agents are under clinical development. Increasing observations from Alimonti team (Chen, Nature Genetics 2018) suggest that the rewired tumour-related metabolic phenotype mainly relies on enhanced oxidative phosphorylation and lipogenesis. These metabolic alterations contribute to tumor initiation and progression. By integrating animal experiments, metabolomics approaches, and bioinformatic tools, we investigate the interactions between metabolism and prostate cancer to identify new metabolic vulnerabilities that can be effectively targeted for cancer treatment.